-
Something wrong with this record ?
Mass spectrometric analysis of purine de novo biosynthesis intermediates
L. Mádrová, M. Krijt, V. Barešová, J. Václavík, D. Friedecký, D. Dobešová, O. Součková, V. Škopová, T. Adam, M. Zikánová,
Language English Country United States
Document type Journal Article, Research Support, Non-U.S. Gov't
Grant support
NV15-28979A
MZ0
CEP Register
Digital library NLK
Full text - Article
Source
NLK
Directory of Open Access Journals
from 2006
Free Medical Journals
from 2006
Public Library of Science (PLoS)
from 2006
PubMed Central
from 2006
Europe PubMed Central
from 2006
ProQuest Central
from 2006-12-01
Open Access Digital Library
from 2006-10-01
Open Access Digital Library
from 2006-01-01
Open Access Digital Library
from 2006-01-01
Medline Complete (EBSCOhost)
from 2008-01-01
Nursing & Allied Health Database (ProQuest)
from 2006-12-01
Health & Medicine (ProQuest)
from 2006-12-01
Public Health Database (ProQuest)
from 2006-12-01
ROAD: Directory of Open Access Scholarly Resources
from 2006
- MeSH
- Chromatography, Liquid MeSH
- CRISPR-Cas Systems MeSH
- DNA biosynthesis chemistry MeSH
- Gene Editing MeSH
- HeLa Cells MeSH
- Humans MeSH
- Purines biosynthesis chemistry MeSH
- RNA biosynthesis chemistry MeSH
- Tandem Mass Spectrometry * MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
Purines are essential molecules for all forms of life. In addition to constituting a backbone of DNA and RNA, purines play roles in many metabolic pathways, such as energy utilization, regulation of enzyme activity, and cell signaling. The supply of purines is provided by two pathways: the salvage pathway and de novo synthesis. Although purine de novo synthesis (PDNS) activity varies during the cell cycle, this pathway represents an important source of purines, especially for rapidly dividing cells. A method for the detailed study of PDNS is lacking for analytical reasons (sensitivity) and because of the commercial unavailability of the compounds. The aim was to fully describe the mass spectrometric fragmentation behavior of newly synthesized PDNS-related metabolites and develop an analytical method. Except for four initial ribotide PDNS intermediates that preferentially lost water or phosphate or cleaved the forming base of the purine ring, all the other metabolites studied cleaved the glycosidic bond in the first fragmentation stage. Fragmentation was possible in the third to sixth stages. A liquid chromatography-high-resolution mass spectrometric method was developed and applied in the analysis of CRISPR-Cas9 genome-edited HeLa cells deficient in the individual enzymatic steps of PDNS and the salvage pathway. The identities of the newly synthesized intermediates of PDNS were confirmed by comparing the fragmentation patterns of the synthesized metabolites with those produced by cells (formed under pathological conditions of known and theoretically possible defects of PDNS). The use of stable isotope incorporation allowed the confirmation of fragmentation mechanisms and provided data for future fluxomic experiments. This method may find uses in the diagnosis of PDNS disorders, the investigation of purinosome formation, cancer research, enzyme inhibition studies, and other applications.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc19028006
- 003
- CZ-PrNML
- 005
- 20201030125156.0
- 007
- ta
- 008
- 190813s2018 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1371/journal.pone.0208947 $2 doi
- 035 __
- $a (PubMed)30532129
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Mádrová, Lucie $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacký University and University Hospital in Olomouc, Olomouc, Czech Republic. Department of Clinical Biochemistry, University Hospital in Olomouc, Olomouc, Czech Republic.
- 245 10
- $a Mass spectrometric analysis of purine de novo biosynthesis intermediates / $c L. Mádrová, M. Krijt, V. Barešová, J. Václavík, D. Friedecký, D. Dobešová, O. Součková, V. Škopová, T. Adam, M. Zikánová,
- 520 9_
- $a Purines are essential molecules for all forms of life. In addition to constituting a backbone of DNA and RNA, purines play roles in many metabolic pathways, such as energy utilization, regulation of enzyme activity, and cell signaling. The supply of purines is provided by two pathways: the salvage pathway and de novo synthesis. Although purine de novo synthesis (PDNS) activity varies during the cell cycle, this pathway represents an important source of purines, especially for rapidly dividing cells. A method for the detailed study of PDNS is lacking for analytical reasons (sensitivity) and because of the commercial unavailability of the compounds. The aim was to fully describe the mass spectrometric fragmentation behavior of newly synthesized PDNS-related metabolites and develop an analytical method. Except for four initial ribotide PDNS intermediates that preferentially lost water or phosphate or cleaved the forming base of the purine ring, all the other metabolites studied cleaved the glycosidic bond in the first fragmentation stage. Fragmentation was possible in the third to sixth stages. A liquid chromatography-high-resolution mass spectrometric method was developed and applied in the analysis of CRISPR-Cas9 genome-edited HeLa cells deficient in the individual enzymatic steps of PDNS and the salvage pathway. The identities of the newly synthesized intermediates of PDNS were confirmed by comparing the fragmentation patterns of the synthesized metabolites with those produced by cells (formed under pathological conditions of known and theoretically possible defects of PDNS). The use of stable isotope incorporation allowed the confirmation of fragmentation mechanisms and provided data for future fluxomic experiments. This method may find uses in the diagnosis of PDNS disorders, the investigation of purinosome formation, cancer research, enzyme inhibition studies, and other applications.
- 650 _2
- $a CRISPR-Cas systémy $7 D064113
- 650 _2
- $a chromatografie kapalinová $7 D002853
- 650 _2
- $a DNA $x biosyntéza $x chemie $7 D004247
- 650 _2
- $a editace genu $7 D000072669
- 650 _2
- $a HeLa buňky $7 D006367
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a puriny $x biosyntéza $x chemie $7 D011687
- 650 _2
- $a RNA $x biosyntéza $x chemie $7 D012313
- 650 12
- $a tandemová hmotnostní spektrometrie $7 D053719
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Krijt, Matyáš, $d 1987- $7 hka2017942408 $u Research Unit for Rare Diseases, Department of Pediatrics and Adolescent Medicine, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic.
- 700 1_
- $a Barešová, Veronika $u Research Unit for Rare Diseases, Department of Pediatrics and Adolescent Medicine, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic.
- 700 1_
- $a Václavík, Jan $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacký University and University Hospital in Olomouc, Olomouc, Czech Republic. Department of Clinical Biochemistry, University Hospital in Olomouc, Olomouc, Czech Republic.
- 700 1_
- $a Friedecký, David $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacký University and University Hospital in Olomouc, Olomouc, Czech Republic. Department of Clinical Biochemistry, University Hospital in Olomouc, Olomouc, Czech Republic. Laboratory of Inherited Metabolic Disorders, Department of Clinical Chemistry, University Hospital in Olomouc, Olomouc, Czech Republic.
- 700 1_
- $a Dobešová, Dana $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacký University and University Hospital in Olomouc, Olomouc, Czech Republic.
- 700 1_
- $a Škopová, Václava $7 xx0248662 $u Research Unit for Rare Diseases, Department of Pediatrics and Adolescent Medicine, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic.
- 700 1_
- $a Součková, Olga $7 xx0248653 $u Research Unit for Rare Diseases, Department of Pediatrics and Adolescent Medicine, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic.
- 700 1_
- $a Adam, Tomáš $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacký University and University Hospital in Olomouc, Olomouc, Czech Republic. Department of Clinical Biochemistry, University Hospital in Olomouc, Olomouc, Czech Republic. Laboratory of Inherited Metabolic Disorders, Department of Clinical Chemistry, University Hospital in Olomouc, Olomouc, Czech Republic.
- 700 1_
- $a Zikánová, Marie $7 xx0248652 $u Research Unit for Rare Diseases, Department of Pediatrics and Adolescent Medicine, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic.
- 773 0_
- $w MED00180950 $t PloS one $x 1932-6203 $g Roč. 13, č. 12 (2018), s. e0208947
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/30532129 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20190813 $b ABA008
- 991 __
- $a 20201030125154 $b ABA008
- 999 __
- $a ok $b bmc $g 1433155 $s 1066466
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2018 $b 13 $c 12 $d e0208947 $e 20181210 $i 1932-6203 $m PLoS One $n PLoS One $x MED00180950
- GRA __
- $a NV15-28979A $p MZ0
- LZP __
- $a Pubmed-20190813